OptimizeRx Corporation
OPRX
$7.77
$0.628.67%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 88.18M | 83.20M | 78.21M | 71.52M | 62.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.18M | 83.20M | 78.21M | 71.52M | 62.81M |
| Cost of Revenue | 32.98M | 31.65M | 30.54M | 28.62M | 25.29M |
| Gross Profit | 55.20M | 51.55M | 47.67M | 42.90M | 37.51M |
| SG&A Expenses | 59.12M | 58.58M | 56.41M | 54.28M | 51.99M |
| Depreciation & Amortization | 4.24M | 3.61M | 3.01M | 2.40M | 1.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.34M | 93.85M | 89.95M | 85.30M | 79.14M |
| Operating Income | -8.16M | -10.64M | -11.74M | -13.78M | -16.33M |
| Income Before Tax | -33.33M | -26.26M | -25.29M | -25.13M | -13.72M |
| Income Tax Expenses | -9.16M | -8.34M | -7.22M | -7.56M | 33.00K |
| Earnings from Continuing Operations | -24.17 | -17.91 | -18.07 | -17.57 | -13.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.17M | -17.91M | -18.07M | -17.57M | -13.75M |
| EBIT | -8.16M | -10.64M | -11.74M | -13.78M | -16.33M |
| EBITDA | -4.13M | -7.14M | -8.79M | -11.38M | -14.35M |
| EPS Basic | -1.33 | -1.00 | -1.03 | -1.02 | -0.81 |
| Normalized Basic EPS | -0.45 | -0.48 | -0.46 | -0.46 | -0.51 |
| EPS Diluted | -1.34 | -1.01 | -1.04 | -1.03 | -0.81 |
| Normalized Diluted EPS | -0.45 | -0.48 | -0.46 | -0.46 | -0.51 |
| Average Basic Shares Outstanding | 72.53M | 70.84M | 69.58M | 68.50M | 67.88M |
| Average Diluted Shares Outstanding | 72.53M | 70.84M | 69.58M | 68.50M | 67.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
